[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"idiopathic-infertility\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:idiopathic-infertility":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":5},"100624079","biological-aging-hallmarks-guided-integrative-tcm-and-conventional-medicine-in-post-treatment-unexplained-female-infertility-100624079",false,"NCT07404969","Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility","An Interventional Study Evaluating Telomere and Biological Aging Hallmarks Profiling to Guide an Integrative Traditional Chinese and Conventional Medicine Approach in Women With Post-Treatment Unexplained Infertility","TECMI","Inclusion Criteria:\n\n* Biological female participants aged 25 to 42 years.\n* Diagnosis of infertility defined as failure to conceive after at least 12 months of unprotected intercourse and\u002For repeated failure of assisted reproductive technologies (ART), including intrauterine insemination (IUI) and\u002For in vitro fertilization (IVF).\n* History of post-treatment unexplained or functionally idiopathic infertility, defined as persistent infertility despite adequate correction or management of identifiable reproductive conditions (e.g., endometriosis, polycystic ovary syndrome, hormonal imbalance, uterine factors).\n* Eligibility for natural conception attempts and\u002For assisted reproductive technologies according to routine clinical practice.\n* Willingness to undergo biological aging biomarker profiling, including leukocyte telomere analysis.\n* Ability and willingness to comply with study procedures, including the preconception integrative intervention and follow-up assessments.\n* Provision of written informed consent prior to participation.\n\nExclusion Criteria:\n\n* Current pregnancy or breastfeeding at the time of enrollment.\n* Known chromosomal abnormalities or genetic conditions directly impairing fertility (e.g., Turner syndrome).\n* Untreated severe male factor infertility precluding conception by natural or standard ART methods.\n* Active malignancy or history of cancer requiring systemic treatment within the past 5 years.\n* Severe systemic disease or medical condition contraindicating pregnancy or participation in ART (as determined by the treating physician).\n* Use of investigational drugs or participation in another interventional clinical trial that could interfere with the study outcomes.\n* Known hypersensitivity or contraindication to components of the integrative intervention, as determined by clinical assessment.\n* Any condition which, in the opinion of the investigator, would interfere with safe participation or interpretation of study results.","FEMALE","25 Years","42 Years",{"count":21,"type":22},15,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to determine whether telomere profiling and other biological aging hallmarks can help identify underlying mechanisms of persistent infertility in women with post-treatment unexplained infertility. The study also evaluates whether a personalized integrative treatment guided by these biomarkers can improve reproductive outcomes.\n\nThe study includes women aged 25 to 42 years who continue to experience infertility despite appropriate management of identifiable reproductive conditions and repeated attempts with assisted reproductive technologies (ART), such as intrauterine insemination (IUI) or in vitro fertilization (IVF).\n\nThe main questions this study aims to answer are:\n\n* Can telomere and biological aging hallmarks profiling identify a biological aging phenotype associated with infertility?\n* Can an integrative treatment guided by these profiles improve clinical pregnancy outcomes?\n\nParticipants will:\n\n* Undergo a baseline reproductive evaluation and blood-based assessment of telomeres and aging hallmarks.\n* Receive an integrative approach combining Traditional Chinese Medicine (TCM), targeted nutritional support, and standard fertility care.\n* Proceed with natural conception attempts or standard assisted reproductive technologies following the preconception phase.\n* Participants will be followed to assess pregnancy outcomes and changes in biological aging hallmarks.",[28,29,30,31,32],"Idiopathic Infertility","Infertility Unexplained","Infertility (IVF Patients)","Infertility Assisted Reproductive Technology","Infertility Female",[34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57],"Telomere dysfunction","Telomere attrition","Telomere biology","Cellular aging","Mitochondrial dysfunction","Cellular senescence","Reproductive aging","Functional infertility","Idiopathic infertility","Post-treatment unexplained infertility","Oocyte quality","Endometrial receptivity","Biomarkers of reproductive quality","Single-cell FISH","Leukocyte telomere length","Molecular etiology of infertility","Aging hallmarks","Traditional Chinese Medicine","Integrative fertility therapy","Nutraceutical support","Mitochondrial biogenesis","Oxidative stress","Reproductive resilience","Beyond Genomix","RECRUITING","2026-04-28",{"date":61,"type":62},"2026-04-29","ACTUAL",{"date":64,"type":62},"2025-01-01",{"date":66,"type":22},"2026-12-01",{"name":68,"class":69},"BEYOND GENOMiX SA, AG, Ltd","INDUSTRY"]